Patent
Method of treating a disease condition caused or exacerbated by an HPV
| العنوان: | Method of treating a disease condition caused or exacerbated by an HPV |
|---|---|
| Patent Number: | 7,019,000 |
| تاريخ النشر: | March 28, 2006 |
| Appl. No: | 09/763616 |
| Application Filed: | September 03, 1999 |
| مستخلص: | The invention provides agents and compounds (see (I) and (II)) for use in the treatment or prophylaxis of disease conditions caused or exacerbated by mammalian papillomaviruses, such as human papillomaviruses, as well as methods for the treatment or prevention thereof. In said formulae, R1–R4 and n are as defined herein. |
| Inventors: | Bernard, Hans-Ulrich (Singapore, SG); Tan, Yee Joo (Singapore, SG); Beerheide, Walter (Singapore, SG); Ting, Anthony Eugene (Singapore, SG); Sim, Mui Mui (Singapore, SG) |
| Assignees: | Institute of Molecular & Cell Biology (Singapore, SG) |
| Claim: | 1. A method of treating a disease condition caused or exacerbated by an HPV wherein said disease condition is cervical cancer or precursor lesions thereof, asymptomatic infections of the cervix and genital, common, plantar or planar warts, comprising the administration to a mammal in need thereof of an effective amount of a compound which facilitates disruption of a chelated metal cation domain of a protein encoded for by an HPV gene, wherein the compound is selected from the group of compounds consisting of formulae (I): [chemical expression included] wherein n is selected from 1–5 R 1 –R 4 are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted arylalkyl optionally substituted acyl, optionally substituted heterocyclyl, halo alkyl, arylalkyl, carboxy, carboxy ester and carboxamido; or R 1 and R 2 together, and/or R 3 and R 4 together, independently form a group of formula (a): (CH 2) l —U m —(CH 2) n — (a) wherein: U is CH 2 , O, NH or S; l and n are independently selected from 0 to 6 and m is 0 or 1 when U is CH 2 and m is 1 when U is O, NH or S, such that l+m+n is greater than or equal to 2; and wherein any one or more (CH 2) or NH groups may be further optionally substituted or a pharmaceutically acceptable derivative thereof. |
| Claim: | 2. A method according to claim 1 wherein R 1 and R 2 together, and/or R 3 and R 4 together, independently form a group of formula (a): (CH 2) l —U m —(CH 2) n — (a) wherein: U is selected from CH 2 , O, NH or S; l and n are independently selected from 0 to 6 and m is 0 or 1 when U is CH 2 and m is 1 when U is O, NH or S, such that l+m+n is greater than or equal to 2; and wherein any one or more (CH 2) or NH groups may be further optionally substituted. |
| Claim: | 3. A method according to claim 2 wherein U is CH 2 . |
| Claim: | 4. A method according to claim 3 wherein formula (a) is selected from the group consisting of —(CH 2) 2 —, —(CH 2) 3 —, —(CH 2) 4 —, —(CH 2) 5 —, —(CH 2) 6 — and —(CH 2) 7 —. |
| Claim: | 5. A method according to claim 2 wherein U is NH, O, or S and m is 1. |
| Claim: | 6. A method according to claim 2 wherein R 1 and R 2 , and/or R 3 and R 4 , together with the nitrogen to which they are attached independently form a group selected from the group consisting of: [chemical expression included] which may be optionally substituted at a carbon atom, and/or where U is NH, at the nitrogen atom. |
| Claim: | 7. A method according to claim 6 wherein R 1 and R 2 , and/or R 3 and R 4 , together with the nitrogen to which they are attached each independently form an optionally substituted morpholino, thiomorpholino, or piperazino group. |
| Claim: | 8. A method according to claim 2 wherein any —CH 2 — group of formula (a) is optionally substituted by one or more of the groups selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, hydroxy, halo, methoxy, ethoxy, isopropoxy, acetoxy, optionally substituted benzyl, optionally substituted pyridyl, optionally substituted pyrimidyl and optionally substituted phenyl. |
| Claim: | 9. A method according to claim 1 wherein at least one of R 1 –R 4 is independently selected from the group consisting of: hydrogen, optionally substituted phenyl, optionally substituted cyclopropyl, optionally substituted cyclobutyl, optionally substituted cyclopentyl, and optionally substituted cyclohexyl, formyl, acetyl. |
| Claim: | 10. A method according to claim 8 wherein the optional substituent is selected from the group consisting of methyl, ethyl, n-propyl, iso-propyl, hydroxy, halo, methoxy, ethoxy, iso-propoxy, acetoxy, and phenyl. |
| Claim: | 11. A method according to claim 1 wherein at least one of R 1 –R 4 is selected from the group consisting of: —CH 2 -Ph, —CH 2 —C(O)—O—CH 2 CH 3 , —C(O)H, —CH 2 —CH 3 and [chemical expression included] or R 1 and R 2 together and/or R 3 and R 4 together independently form a group selected from the group consisting of: [chemical expression included] |
| Claim: | 12. A method according to claim 1 wherein n is 1, 2 or 3. |
| Claim: | 13. A method according to claim 1 wherein the HPV is HPV-16. |
| Claim: | 14. A method according to claim 13 wherein the protein is the HPV-16 E6 or E7 oncoprotein. |
| Claim: | 15. A method according to claim 1 wherein the HPV is HPV-18. |
| Claim: | 16. A method according to claim 15 wherein the protein is the HPV-18 E6 or E7 oncoprotein. |
| Claim: | 17. A method according to claim 1 where the chelated metal cation domain is a chelated zinc cation domain. |
| Claim: | 18. A method according to claim 17 wherein the chelated zinc domain is the sequence motif cys-X2-cys-X29-cys-X2-cys (SEQ ID NO:2). |
| Claim: | 19. A method of treating a disease condition caused or exacerbated by an HPV which is cervical cancer or precursor lesions thereof, asymptomatic infections of the cervix and genital, common, plantar or planar warts comprising the administration of an effective amount of a compound as defined in claim 1 to a mammal in need thereof. |
| Claim: | 20. A method according to claim 1 wherein the compound is capable of effecting at least 30% zinc release in a TSQ assay and/or inhibits or reduces the binding of an E6 protein to E6AP or E6BP and/or exhibits selective cytotoxicity towards MPV-infected cells. |
| Claim: | 21. A method according to claim 1 wherein the disease or condition is cervical cancer or its HPV associated precursor lesions. |
| Claim: | 22. A method of treating a disease condition caused or exacerbated by an HPV and which is cervical cancer or precursor lesions thereof, asymptomatic infections of the cervix and genital, common, plantar or planar warts comprising the administration of an effective amount of a compound capable of facilitating the disruption of a chelated metal cation domain of a protein encoded for by an HPV gene to a mammal in need thereof, wherein said compound is a compound identified as a compound useful in the treatment of a disease or condition caused or exacerbated by an HPV by a method which comprises contacting a protein molecule containing a chelated metal cation domain, encoded by an HPV gene, with an effective amount of said compound for a time and under conditions sufficient to facilitate disruption of the chelated metal cation domain and directly or indirectly determining the amount of chelated metal cation released wherein the amount of chelated metal cation released is indicative of the disruption of the chelated metal cation domain wherein the compound is selected from the group of compounds consisting of formulae (I): [chemical expression included] wherein n is selected from 1–5 R 1 –R 4 are independently selected from the group consisting of hydrogen, optionally substituted alkyl, optionally substituted alkenyl, optionally substituted alkynyl, optionally substituted aryl, optionally substituted arylalkyl optionally substituted acyl, optionally substituted heterocyclyl, halo alkyl, arylalkyl, carboxy, carboxy ester and carboxamido; or R 1 and R 2 together, and/or R 3 and R 4 together, independently form a group of formula (a): (CH 2) l —U m —(CH 2) n — (a) wherein: U is CH 2 , O, NH or S; l and n are independently selected from 0 to 6 and m is 0 or 1 when U is CH 2 and m is 1 when U is O, NH or S, such that l+m+n is greater than or equal to 2; and wherein any one or more (CH 2) or NH groups may be further optionally substituted or a pharmaceutically acceptable derivative thereof. |
| Claim: | 23. The method according to claim 1 wherein the compound is 4,4-dithiodimorpholine. |
| Claim: | 24. A method according to claim 1 wherein n is 1 or 2. |
| Current U.S. Class: | 5142/278 |
| Patent References Cited: | 562750 September 1993 WO 96/09406 March 1996 |
| Other References: | Sherman et al., Virology 237: 296-306, 1997. cited by other Chen et al., Science 269: 529-531, 1995. cited by other Tong et al., Proc. Natl. Acad. Sci. USA 94: 4412-4417, 1997. cited by other Sedman et al., J. Virol. 65: 4860-4866, 1991. cited by other Lamberti et al., EMBO J. 9: 1907-1913, 1990. cited by other Etscheid et al., Virology 205: 583-585, 1994. cited by other Klingelhutz et al., Nature 380: 79-82, 1996. cited by other Myers and Androphy, The E6 protein, pp III-47-III-57, 1995. cited by other Grossman et al., Oncogene 4: 1089-1093, 1989. cited by other Kanada et al., Virology 185: 536-543, 1991. cited by other Dsouza et al., Trends in Genetics 13: 497-498, 1997. cited by other Chan et al., Virol. 69: 3074-3083, 1995. cited by other Myers et al., Human papillomaviruses, pp II-E6-1-II-E6-7, 1994. cited by other van Ranst et al., J. Gen. Virol. 73: 2653-2660, 1992. cited by other Crook et al., Cell 67: 547-556, 1991. cited by other Dala et al., J. Virol. 70: 683-688, 1996. cited by other Nakagawa et al., Virology 212: 535-542, 1995. cited by other Vousden et al., J. Virol. 63: 2650-2656, 1989. cited by other Bartsch et al., EMBO J. 11: 2283-2291, 1992. cited by other Bosch et al., J. Virology 64: 4743-4754, 1990. cited by other Tummino et al., Proc. Natl. Acad. Sci. USA 93: 969-973, 1996. cited by other Rice et al., J. Medicinal Cham. 39: 3606-3616, 1996. cited by other Rice et al., Science 270: 1194-1197, 1995. cited by other Huibregtse et al., Mol. Cell Biol. 13: 775-784, 1993. cited by other Polyak et al., Nature 389: 300-305, 1997. cited by other Scheffner et al., Proc. Natl. Acad. Sci. USA 91: 8797-8801, 1994. cited by other White et al., Genes Dev. 8: 666-677, 1994. cited by other Tan et al., Cancer Res 55: 4599-4605, 1995. cited by other Beerheide et al., J. Natl. Cancer Inst. 91: 1211-1220, 1999. cited by other Beerheide et al., Bioorganic and Medicinal Chemistry 8: 2549-2560, 2000. cited by other Schifmann, Journal of the National Cancer Institute 87: 1345-1347, 1995. cited by other Edmonds and Vousden, Journal of Virology 63: 2650-2656, 1989. cited by other International Agency for Research on Cancer, IARC Monographs on the evaluation of carcinogenic risks to humans, vol. 64: Human papillomaviruses, 1995, IARC, Lyon, France. cited by other Frederickson et al., J. Neurosci. Meth. 20: 91-103, 1987. cited by other Lehman et al., Carcinogenesis 14: 833-839, 1993. cited by other von Knebel et al., Int. J. Cancer 52: 831-834, 1992. cited by other Derwent Abstract Accession No: 92-303542/37, B05, JP 4-208223, Jul. 27, 1992, Kawaguchi Kagaku Kogyo KK). cited by other Synlett, Aug. 1990, Katritzky, Alan R. et al., “The Synthesis of Bis(N,N-disubstituted amino) Trisulphides”. cited by other Derwent Abstract Accession No: 95-340184/44, B05, JP 7-233057 A, Kinki Daigaku GH, Sep. 5, 1995. cited by other Brain Research vol. 44, No.: 2 (1972), Lycke, E. et al., “The Monoamine Metabolism in Virol Encephalitides of the Mouse II, Turnover of Monoamines in Mice Infected with Herpes Simplex Virus”. cited by other Derwent Abstract Accession No: 86-282536/43, B03, C02, JP 1207376A, Toyo Soda Mfg. KK, Sep. 13, 1986. cited by other Derwent Abstract Accession No: 88-245781/35 A12, JP 3-178148 A, Nippon Oil Seal Ind, Jul. 22, 1988. cited by other Derwent Abstract Accession No: 91-038784/05, S03, JP 2-304346 A, Nihon Parkerizing, Dec. 18, 1990. cited by other Derwent Abstract Accession No: 91-122584/17, B03, JP 3-063258 A, Kuraray KK, Mar. 19, 1991. cited by other Virology vol. 243, pp. 287-292, 1998, Ott, David E. et al., “Inhibition of Friend Virus Replication by a Compound that Reacts with the Nucleocapsid Zinc Finger: Anti-retroviral Effect Demonstrated in Vivo”, abstract: fourth, fifth, tenth and twelfth compounds of Table 1. cited by other Journal of Medicinal Chemistry, vol. 40, No: 13 (1997) pp. 1969-1976, McDonnell, Nazli, B. et al., “Zinc Ejection as a New Rationale for the Use of Cystamine and Related Disulfide-containing Antiviral Agents in the Treatment of AIDS”, abstract; figures 1, 2; Table 1; p. 1973 last paragraph to p. 1974 first paragraph. cited by other Techniques in Protein Chemistry VIII (Symp Protein Soc), 10th (1997), Meeting Date 1996, pp. 231-244, Chertova, E. et al., “Reaction of HSV-1 NC p7, Zinc Fingers with Electrophilic Reagents”, pp. 231-232, 235-237, 241-242. cited by other Drug Metabolism and Disposition: The Biological Fate of Chemicals, vol. 24, No: 12 (1996), pp. 1395-1400 (Hathout, Yetrib et al.), “Characterisation of Intermediates in the Oxidation of Zinc Fingers in Human Immunodeficiency Virus Type I Nucleocapsid Protein P7”, abstract, figure 1, p. 1397, column I, second paragraph, p. 1398, column 2, second paragraph. cited by other Journal of Medicinal Chemistry, vol. 39, No: 19 (1996) pp. 3606-3616 (Rice, William G. et al), “Evaluation of Selected Chemotypes in Coupled Cellular and Molecular Target-Based Screens Identifies Novel HIV-I Zinc Finger Inhibitors”, abstract, p. 3608 column 2 last paragraph, Table 10. cited by other Journal of Virology, vol. 70, No: 8 (1990) pp. 4966-4972 (Rein, Alan et al.), “Inactivation of Murine Leukemia Virus by Compounds that React with the Zinc Finger in the Viral Nucleocapsid Protein”, abstract, p. 4970 first paragraph. cited by other Carcinogenesis, vol. 9, No: 9 (1988) pp. 1547-1551 (Rotstein, Joel B. et al), “Effect of Exogenous Glutathione on Tumour Progression in the Murine Skin Multistage Carcinogenesis Model”, abstract, p. 1547 last paragraph to p. 1548 first paragraph, p. 1549 first paragraph, figure 2. cited by other Chemical Abstracts 102:8009 Rubber Chem Technol (1984), vol. 57 No: 4 pp. 744-754 RN 86796-75-0, 86796-78-3, 86796-79-4. cited by other Chemical Abstracts 111:146042 Chromatographia (1989) vol. 27 No: 3-4 pp. 113-117. cited by other Chemical Abstracts; RN 95255-69-9. cited by other Chemical Abstracts; RN 103-34-4. cited by other |
| Assistant Examiner: | Kwon, Brian-Ying S. |
| Primary Examiner: | Low, Christopher S. F. |
| Attorney, Agent or Firm: | Bacon & Thomas |
| رقم الانضمام: | edspgr.07019000 |
| قاعدة البيانات: | USPTO Patent Grants |
| الوصف غير متاح. |